Herpesvirus saimiri (HVS) is the prototype gammaherpesvirus of the Rhadinovirus genus (8, 9) . HVS causes a persistent asymptomatic infection in its natural host, the squirrel monkey (Saimiri sciureus); however, upon experimental transfer to other New World primates, HVS infection results in fulminant polyclonal T-cell lymphomas and lymphoproliferative diseases (8, 9) . In addition, HVS subgroups A and C possess the ability to immortalize common marmoset T lymphocytes to interleukin-2-independent proliferation (6, 34) . Moreover, subgroup C viruses are capable of transforming human, rabbit, and rhesus monkey lymphocytes in vitro (3, 4) . HVS can also stably transduce a variety of human cell lines, where they harbor the viral genome as a multiple high-copy-number nonintegrating circular episome without production of virus particles (12, 16, (28) (29) (30) .
The genome of HVS (strain A11) comprises a unique internal low-GϩC DNA segment (L-DNA) of approximately 110 kbp, flanked by a variable number of 1,444-bp high-GϩC tandem repetitions (H-DNA) (1) . Sequence analysis indicates HVS shares significant homology with other herpesviruses of oncogenic potential, including Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (or human herpesvirus 8) (KSHV), and murine gammaherpesvirus 68 (MHV-68) (1, 22, 27, 35) . Their genomes are predominantly colinear with homologous genes in approximately the same locations and orientation. However, conserved gene blocks are separated by genes unique to each respective virus. Like all Rhadinoviruses, the HVS genome encodes a number of cellular homologues whose products may have a role in transformation, immune evasion, and long-term persistence of the viral episome (1, 8) .
The open reading frame (ORF) 50 gene product, also known as the replication and transcription activator (Rta), is an immediate-early gene which is well conserved among all gamma-2 herpesviruses (5, 7, 40) . The KSHV, MHV-68, and HVS ORF 50 homologues have all been shown to play a pivotal role in regulating the latent-lytic switch in gamma-2 herpesviruses (10, 11, 20, 33, 43) . For example, overexpression of the larger spliced ORF 50a gene in a HVS-persistently infected A549 cell line, where the HVS DNA is stably maintained as nonintegrated circular episomes, was sufficient to reactivate the entire lytic replication cycle producing infectious virus particles (10) .
The ORF 50 homologues function as sequence-specific transactivators (5) . Analysis of the major HVS ORF 50a gene product has shown that it activates transcription following direct interactions with specific response elements (REs) within HVS promoters (23, 36, 37, 41, 42) . Recently, we have identified a DNA binding domain within ORF 50a which has a high degree of homology to the DNA binding domain encoded by mammalian high-mobility group A (HMGA) chromosomal proteins with an AT-hook. Deletion and site-directed mutagenesis have demonstrated that this domain, encompassing residues 399 to 412, is required for ORF 50-mediated transactivation and binding to the ORF 50 RE. Moreover, ORF50⌬AT-hook is capable of functioning as a trans-dominant mutant, leading to a reduction in virus replication (36) . Once bound, HVS ORF 50a recruits and interacts with the TATA binding protein (17) , suggesting that it recruits components of the TFIID complex, allowing transcription initiation by RNA polymerase II.
Further analysis of the ORF 50 REs have identified two distinct types within HVS gene promoters. The first, contained within the major DNA binding protein (ORF 6) and ORF 57 promoters comprises a consensus-specific sequence motif, CCN 9 GG, (41, 42) Analysis of the HVS genome suggests that at least 10 HVS gene promoters contain similar CCN 9 GG REs. This type of RE has significant homology to the EBV Rta RE consensus sequence, GNCCN 9 GGNG (13) (14) (15) . It has been shown by guanine methylation studies that the CCN 9 GG motif is essential for EBV Rta binding and suggests that Rta binds to adjacent major grooves of the DNA (13) (14) (15) . In contrast, HVS ORF 50a is capable of stimulating its own promoter via direct binding to an alternative AT-rich sequence RE within its promoter (37) . Sequence analysis of the RE demonstrates that it has no direct homology with the CCN 9 GG motif containing REs (37) . Interestingly, the alternative ORF 50 REs both confer ORF 50 responsiveness to an enhancerless promoter; however, stimulation levels vary, which may suggest a further regulatory step of the lytic temporal cascade (37) .
In this report, we aimed to determine whether HVS ORF 50a could transactivate DE genes which do not contain the consensus CCN 9 GG motif within their gene promoter. One such example is the DE ORF 9 promoter encoding the HVS DNA polymerase. Here we demonstrate that the ORF 9 promoter is responsive to the ORF 50a protein. We show that the ORF 50a protein binds directly to a nonconsensus 28-bp ATrich RE. Moreover, the ORF 9 promoter contains multiple CCAAT enhancer binding protein alpha (C/EBP␣) elements and coexpression of ORF 50a and C/EBP␣ results in a synergistic effect on the activation of the ORF 9 promoter.
MATERIALS AND METHODS
Plasmid constructs. In order to generate an ORF 9 promoter reporter gene construct, the ORF 9 gene promoter was PCR amplified with primers 5Ј-CGG GGT ACC GTT AAT GTA GCA AGC GGC GC and 5Ј-CTA GCT AGC GTC AAG ACA GCA ACT CAG. These oligonucleotides incorporated KpnI and NheI restriction sites, respectively, for convenient cloning of the PCR product. PCR (30 cycles [1 cycle consists of 1 min at 92°C, 1 min at 58°C, and 2 min at 72°C]) was performed with 4 units of Pfu (Stratagene). This fragment was inserted upstream of the luciferase coding region in pGL3-basic (Promega) to derive pORF9-Luc. The 5Ј ORF 9 promoter deletion series was constructed by PCR amplification using the forward primer ⌬1 (5Ј-CGG GGT ACC GTT CAC ATT TCT ATT AAT AGG), ⌬2 (5Ј-CGG GGT ACC CCC AGA TGT TGA GAA ATC), ⌬3 (5Ј-CGG GGT ACC GGA ATG CAT AAC ATG CAG), ⌬3.5 (5Ј-CGG GGT ACC GAG CTG CTA GAC CGT C), and ⌬4 (5Ј-CGG GGT ACC GCG TAA GCG ATC TGG TTA); these oligonucleotides incorporated KpnI restriction sites for the convenient cloning of the PCR products. Each fragment was inserted into the luciferase reporter vector, pGL3-basic to derive pORF9⌬1 to pORF9⌬4 (see Fig. 2a ). All constructs were confirmed by DNA sequencing (data not shown).
In order to further assess the putative ORF 50 RE within the ORF 9 promoter comprising 20307 to 20335 bp of the published sequence, oligonucleotides encompassing this region, 5Ј-AAG CAT ATA AGA AAA AGA AGA ACA AAG A and 5Ј-TCT TTG TTC TTC TTT TTC TTA TAT GCT T, were cloned into pGL3-promoter (Promega), which contains the luciferase reporter gene under the control of a minimal simian virus 40 (SV40) promoter. The oligonucleotides were annealed to form blunt-ended fragments and then cloned directly in either orientation into pGL3-promoter previously digested with SmaI, to derive pGL3-9RE1 and pGL3-9RE2.
In order to generate an ORF 9 promoter construct lacking the putative C/EBP␣ response element, a deletion construct lacking the sequence between 20286 and 20314 bp was constructed by a PCR-based method. The ORF 9 promoter was PCR amplified in two fragments, thereby removing the C/EBP␣ binding site, using the following sets of primers: for fragment 1, primer A (5Ј-CGG GGT ACC GTT AAT GTA GCA AGC GGC GC) and primer B (TTC CCC GGG CCA AGC AAA ATT TGT TTT AAT TG); for fragment 2, primer C (5Ј TTC CCC GGG GCA AGA AGC ATA TAA GAA AAA AAG) and primer D (5Ј-CTA GCT AGC GTC AAG ACA GCA ACT CAG). Primer A and D oligonucleotides incorporated KpnI and NheI and primer B and C incorporated SmaI restriction sites, respectively, for convenient cloning of the PCR product. PCR (30 cycles [1 cycle consists of 1 min at 92°C, 1 min at 50°C, and 2 min at 72°C]) was performed with 4 units of Pfu (Stratagene). These fragments were inserted by triple-way ligation upstream of the luciferase coding region in pGL3-basic (Promega) to derive pORF9⌬C/EBP-Luc.
Plasmids encoding C/EBP␣ and C/EBP␤ were kindly provided by C. Heckman, Stanford University School of Medicine. These constructs contained the respective cDNAs in plasmid pcDNA3.1 (Invitrogen); to generate a myc-tagged version, the coding region was excised from pC/EBP␣ as a HindIII-XbaI fragment and cloned into pcDNA3.1-myc (Invitrogen), deriving pC/EBP␣-myc. Plasmid constructs pEGFP, p50GFP, p50GFP⌬AT-hook, pGL3-50RE, and pGL3-6RE have been previously reported (36) .
Cell culture, viruses, and transfections. 293T cells were maintained in Dulbecco modified Eagle medium (Life Technologies) supplemented with 10% fetal calf serum. Plasmids used in the transfections were prepared using QIAGEN plasmid kits according to the manufacturer's directions. 293T cells were seeded at 5 ϫ 10 5 cells per 35-mm-diameter petri dish 24 h prior transfection. Transfections were performed using Lipofectamine (Invitrogen) as described by the manufacturer, using 2 g of the appropriate DNAs. HVS (strain A11) was propagated in owl monkey kidney (OMK) cells which were maintained in Dulbecco modified Eagle medium (Life Technologies) supplemented with 10% fetal calf serum.
Luciferase reporter assay. Transfected 293T cells (1 ϫ 10 6 ) were harvested in 200 l of passive lysis buffer (Promega). Quantitation of relative light units was determined using the dual-luciferase Stop & Glo reagent using the manufacturer's directions (Promega) and a Berthold luminometer (EG& G Berthold) with a dual-injector system. All assays were performed in triplicate, and each experiment was repeated a minimum of three times.
RT-PCR analysis. RNA was extracted from 293T cells 24 h posttransfection. Cells were lysed using Trizol reagent (Invitrogen). Chloroform (0.2 ml) was then added, and the solution was vortex mixed for 20 s and stored at 20°C for 15 min. Samples were centrifuged for 15 min at 4°C, and the aqueous phase containing nucleic acids was precipitated using 0.5 ml of isopropanol. After the pellet was washed with 70% ethanol, it was resuspended in 50 l of water and stored at Ϫ70°C. First-strand cDNA was reverse transcribed using Superscript II reverse transcriptase (Life Technologies) and an oligo(dT) primer. Reverse transcription-PCR (RT-PCR) was then performed using the following sets of forward and reverse primers (indicated by the f or r letter at the end of the primer designation, respectively): ORF50f, 5Ј-CTG GAA TAG TCT CTA CAA CAT TAG CA; ORF50r, 5Ј-CCG CTC GAG GTT TGG ATC TAT GTT GCG ACT CTG; LUCf, 5Ј-GCG CCA TTC TAT CCG CTG; LUCr, 5Ј-ATC GAA GGA CTC TGG CAC; hGAPDHf, 5Ј-CCA CCC ATG GCA AAT TCC ATG GCA; and hGAPDHr, 5Ј-TCT AGA CGG CAG GTC AGG TCC ACC]). PCR (30 cycles [1 cycle consists of 1 min at 92°C, 1 min at 55°C, and 1 min at 72°C]) was performed with 4 units of Taq polymerase (Promega).
Gel retardation analysis. The following sets of fluorescein-labeled oligonucleotides, set 1 (5Ј-GGA ATG CAT AAC ATG CAG CAA GAA GCA T and 5Ј-ATG CTT CTT GCT GCA TGT TAT GCA TTC C) and set 2 (5Ј-AAG CAT ATA AGA AAA AGA AGA ACA AAG A and 5Ј-TCT TTG TTC TTC TTT TTC TTA TAT GCT T) (Invitrogen) were annealed and then incubated with nuclear extracts of untransfected cells or cells transfected with pORF50a or p50GFP⌬AT-hook prepared by the method of Andrews and Faller (2) . The binding reactions were performed in 20 l of 100 mM KCl, 20 mM HEPES (pH 7.3), 1% glycerol, 0.2 mM EDTA, 5 mM MgCl 2 , 4 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride with 1 g of poly(dI-dC) as a nonspecific competitor. The protein-nucleic acid complexes were separated on a 5% polyacrylamide gel, run in 1% Tris-borate-EDTA buffer, and detected using a Typhoon 9410 variable-mode imager (Amersham).
In vitro transcription/translation. Protein expression from ORF 50, C/EBP␣, and C/EBP␤ was performed by in vitro transcription/translation using the TNT system (Promega) according to the manufacturer's instructions. Transcription Coimmunoprecipitation assays. 293T cells were transfected using 2 g of the appropriate DNAs. After 24 h, cells were harvested and lysed with lysis buffer (0.3 M NaCl, 1% Triton X-100, 50 mM HEPES buffer, pH 8.0) containing protease inhibitors (leupeptin and phenylmethylsulfonyl fluoride). For each immunoprecipitation, 50 l of the anti-ORF 50 polyclonal antibody (17) was incubated with protein A-Sepharose beads (Pharmacia Biotech) for 16 h at 4°C. The beads were then pelleted and washed four times in phosphate-buffered saline (PBS). Each cell lysate was then added to the beads and incubated for 16 h at 4°C. The beads were then pelleted and washed four times in lysis buffer and resuspended in Laemmli buffer, and precipitated polypeptides were resolved on a 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel.
Immunoblot analysis. Polypeptides were resolved on 12% SDS-polyacrylamide gels and then soaked for 10 min in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol [vol:vol] ). The proteins were transferred to nitrocellulose membranes by electroblotting for 3 h at 250 mA. After transfer, the membranes were soaked in PBS and blocked by preincubation with 2% (wt/vol) nonfat milk powder for 2 h at 37°C. Membranes were incubated with a 1:2,000 dilution of anti-myc (Sigma) antibody or 1:1,000 dilution of anti-green fluorescent protein (GFP) (Clontech) antibody, washed with PBS, and then incubated for 1 h at 37°C with a 1:1,000 dilution of secondary immunoglobulin conjugated with horseradish peroxidase (Dako) in blocking buffer. After five washes with PBS, the nitrocellulose membranes were developed using an ECL kit (Pierce).
Chromatin immunoprecipitation (ChIP) assays. OMK cells seeded at 5 ϫ 10 5 cells per 35-mm-diameter petri dish, were infected at a multiplicity of infection of 1. After 24 h, the cells were harvested and ChIP assays performed using the ChIP assay kit (Upstate Biotechnology). Chromatin extraction, cross-linking, sonication, immunoprecipitation, agarose bead elution, and protein removal were carried out according to the manufacturer's protocol. DNA recovered from immunoprecipitates with anti-ORF 50, anti-C/EBP␣ (Santa Cruz), or anti-ORF 57 monoclonal antibody was used as a template for PCR amplifications. The following specific primers for the HVS ORF 9 promoter were used: 5Ј-CGG GGT ACC CCC AGA TGT TGA GAA ATC and 5Ј-CTA GCT AGC GTC AAG ACA GCA ACT CAG. These generated a 291-bp region promoter encompassing 20216 and 20507 bp of the published sequence. Primers ORF73f (5Ј-CGC GGA TCC ATG GAA GCA GGA CCA AGT ACT CCA) and ORF73r (5Ј-CCG CTC GAG CCT TCT ATA GGC AGG CTT TTG CT-3), specific for the HVS ORF 73 coding region, were used as a negative control to detect a nonpromoter region. The PCR products were analyzed by electrophoresis on a 1.2% agarose gel.
RESULTS
The ORF 50a protein transactivates the DE ORF 9 promoter and requires the AT-hook DNA binding domain. We have previously shown that the HVS ORF 50a protein can transactivate a range of DE HVS promoters which contain a consensus ORF 50 RE, such as the ORF 6 and ORF 57 promoters (41, 42) . However, not all DE genes contain such a consensus RE. We have also shown that the ORF 50a protein can stimulate its own promoter via binding to an AT-rich response element (37) . Therefore, we aimed to determine whether the ORF 50a protein can activate DE gene promoters which contain AT-rich elements with their promoter elements. One such promoter is the DE ORF 9 DNA polymerase gene promoter.
To determine whether ORF 50a was capable of stimulating the ORF 9 gene promoter, the putative ORF 9 promoter situated between 20034 and 20507 bp of the HVS genome (1) was PCR amplified and cloned upstream of the luciferase reporter gene to derive pORF9-Luc. 293T cells were then transfected with either 1 g of pEGFP, p50GFP, or p50GFP⌬AT-hook (which contains a deletion of the ORF50 DNA binding domain) (36) in the presence of 1 g of pORF9-Luc. Cells were harvested 30 h posttransfection, and the protein concentration of each sample was calculated using the DC protein assay kit (Bio-Rad). Moreover, to confirm that the transfection efficiency of these experiments was normalized, immunofluorescence was undertaken to ensure that a comparable number of cells was transfected. In addition, 100 g of cell extracts was analyzed by Western blotting using a primary monoclonal GFP antibody (Clontech) to demonstrate comparable expression between assays (data not shown). An equal amount of cell extracts was then assayed for luciferase activity by standard methods. Results showed that p50GFP was able to stimulate the ORF 9 promoter to high levels, suggesting that the ORF 50a protein can activate a DE promoter which does not contain a consensus ORF 50 RE (Fig. 1) . In contrast, stimulation was drastically reduced, by approximately 95%, using p50GFP⌬AT-hook, suggesting that ORF 50a stimulates the ORF 9 gene via direct binding to the promoter.
Mapping the minimal domain within the ORF 9 promoter that is required for ORF 50a stimulation. To map the ORF 50a responsive regions within the ORF 9 promoter, a series of further promoter deletions were generated (Fig. 2a) . The promoter fragments were PCR amplified, and resulting products were cloned upstream of the luciferase reporter gene, deriving pORF9⌬1 to pORF9⌬4.
293T cells were transfected with either 1 g of pEGFP or p50GFP in the presence of 1 g of pORF9⌬1 to pORF9⌬4. Cells were assayed for luciferase activity, and the data were normalized as described above. p50GFP was capable of stimulating pORF9⌬1 to pORF9⌬3 to levels comparable to that with the full-length promoter; however, stimulation drastically decreased between ⌬3 and ⌬4. The luciferase activity of pORF9⌬4 is only 15% of the activity of pORF9⌬3 (Fig. 2b) . These data suggest that the region required by ORF 50a is within the 100 bp between ⌬3 and ⌬4, comprising 20286 to 20381 bp of the published sequence (1).
To finely map the ORF 50a RE within the ORF 9 promoter, a further deletion within the mapped region was generated (Fig. 2c) . The promoter fragment was PCR amplified and subsequently cloned upstream of the luciferase reporter gene as previously described, deriving pORF9⌬3.5. 293T cells were then transfected with 1 g of p50GFP in the presence of 1 g of pORF9⌬3, pORF9⌬3.5, or pORF9⌬4 and assayed for luciferase activity as described previously (Fig. 2d) . The results demonstrated that p50GFP was capable of stimulating pORF9⌬3 to levels similar to those previously reported. However, deletion of the region between ⌬3 and ⌬3.5 resulted in the level of ORF 50a stimulation returning to a level comparable to that with ⌬4, approximately 15% of wild-type levels. This, therefore, suggests that the element(s) responsible for ORF 50a stimulation lies between ⌬3 and ⌬3.5, comprising 20286 to 20335 bp of the published sequence within the ORF 9 promoter.
The ORF 50a protein binds directly to an AT-rich sequence within the ORF 9 promoter. To assess whether the ORF 50a protein binds directly to this region encompassing ⌬3 and ⌬3.5 of the ORF 9 promoter, gel retardation experiments were performed using two sets of overlapping oligonucleotides spanning the region, termed set I-II (Fig. 3a) . The fluoresceinlabeled oligonucleotides were incubated with 2.5 l of nuclear extracts from untransfected or p50GFP-or p50GFP⌬AT-hook-transfected 293T cells. The protein-nucleic acid complexes were then separated on a 4% polyacrylamide gel and detected by using a variable-mode imager (Fig. 3b) . Results show the formation of a retarded complex with p50GFP-transfected cell extracts when incubated with oligonucleotide set II. No complexes were identified in the presence of 50GFP⌬AT-hook, the mutant ORF 50a protein which lacks the DNA binding domain, suggesting that ORF 50a directly binds the ORF 9 promoter between 20307 and 20335 bp of the published sequence. Moreover, to demonstrate that the retarded complex detected is specific for ORF 50a, three further assays were performed. Firstly, the electrophoretic mobility shift assays (EMSAs) were repeated in the presence of 2.5 l of control reticulocyte lysate or in vitro-translated ORF 50. A retarded complex was detected, demonstrating that ORF 50 directly binds to a RE contained within set II oligonucleotides (Fig.  3bii) . Secondly, a supershift assay was undertaken using a monoclonal GFP antibody (Clontech) and a control B23 antibody (Santa Cruz) and the set II oligonucleotides. Two micrograms of GFP or control antibody was added to the binding reaction mixture described above and incubated for 15 min. A clear shift of the p50GFP retarded complex was detected (Fig.  3biii) , in contrast to the control antibody (Fig. 3biv) , demonstrating specificity for ORF 50a. However, a complete supershift of the ORF 50-GFP antibody complex was not observed; this was probably due to insufficient amounts of antibody being used in the assay. Thirdly, a competition assay was performed using increasing quantities of unlabeled oligonucleotides spanning the ORF 50 RE present within the ORF 6 promoter (42) or an unlabeled random oligonucleotide. The ORF 6 promoter competed out the binding reaction with labeled set II oligonucleotides (Fig. 3bv) , in contrast to the random oligonucleotides (Fig. 3bvi) , demonstrating that this retarded complex is specific for the ORF50a protein.
The ORF 50 response element within the ORF 9 promoter can function as an enhancer element. To further confirm the specificity of ORF 50a binding, the sequences between 20307 and 20335 bp of the published sequence (1) were cloned upstream of a heterologous promoter to determine whether they can confer ORF 50a responsiveness. Set II oligonucleotides were cloned by blunt-end ligation in both possible orientations into pGL3-promoter, which contains the luciferase reporter gene under the control of a minimal SV40 promoter, deriving pGL3-9REI and pGL3-9RE2 (Fig. 4a) . Moreover, to compare the specificity of the ORF 9 promoter RE to previously identified REs, similar constructs were produced containing the REs from the ORF 6 and ORF 50 promoters (37) . 293T cells were then transfected with 1 g of pGL3-promoter, pGL3-50RE1, pGL3-9RE2, pGL3-6RE, or pGL3-9RE in the presence of 1 g of pEGFP or p50GFP and assayed for luciferase activity by standard methods (Fig. 4b) . Results demonstrated FIG. 3 . ORF 50 is capable of binding to a 2-bp AT-rich sequence within the ORF 9 promoter. (a) Schematic representation of the oligonucleotide primers spanning the ORF 50 RE within the ORF 9 promoter. (b) (i) EMSAs were performed using fluorescein-labeled oligonucleotides spanning the ORF 9 promoter. Each labeled set of oligonucleotides was incubated with nuclear extracts prepared from untransfected or p50GFP-or p50GFP⌬AT-hook-transfected 293T cells.
(ii) To demonstrate that ORF 50 interacts directly with set II oligonucleotides, oligonucleotides were incubated with control reticulocyte lysate or in vitro-translated ORF 50 and separated on a polyacrylamide gel.
(iii) To demonstrate the specificity of ORF 50 binding, EMSAs were performed by the addition of primary monoclonal GFP antibody (Ab) (rightmost lane). (iv) To show the specificity of the GFP antibody, EMSAs were repeated with a control antibody (Ab). (v) To demonstrate the specificity of the ORF 50 interaction, increased quantities of unlabeled oligonucleotides spanning the ORF 50 RE present within the ORF 6 promoter were used to compete out the binding reaction. (vi) To show that the competition was specific to the ORF 6 oligonucleotides, EMSAs were repeated with a random oligonucleotide.
that p50GFP was able to increase luciferase activity to significant levels from all four RE constructs. This demonstrates that the sequences with the ORF 9 promoter RE are able to confer ORF 50a responsiveness to a heterologous promoter in either orientation and may function as an enhancer sequence. Levels of activity were similar between constructs containing the REs identified within the ORF 50 and ORF 9 promoter, which both contain AT-rich REs. In contrast, activation levels were 70% higher using the construct containing the canonical ORF 6 promoter RE. This variation in activity of ORF 50-responsive demonstrated that C/EBP␣ is involved in KSHV ORF 50-mediated transactivation of DE promoters (38, 39) . Therefore, the potential involvement of C/EBP␣ on the ORF 50a stimulation of the ORF 9 promoter was further investigated. To this end, 293T cells were transfected with either 1 g of pEGFP, p50GFP, or pC/EBP␣ in the presence of 1 g of pORF9-Luc. Cells were assayed for luciferase activity, and the data were normalized as described above (Fig. 5b) . As a further control, RT-PCR was performed to demonstrate that ORF 50a was expressed in similar quantities in all transfected cells (Fig. 5c) . Results showed that no significant increase in luciferase activity was observed in the presence of C/EBP␣ alone; in contrast, ORF50a activated the ORF 9 promoter to levels similar to those previously shown. However, upon coexpression of ORF 50a and C/EBP␣, ORF 9 promoter activity was significantly enhanced to levels of approximately 160% of activity compared to ORF 50a alone (Fig. 5b) . Therefore, this suggests that ORF 50a and C/EBP␣ may have a synergistic effect on the activation of the ORF 9 promoter.
To ascertain whether this synergistic activation of the ORF 9 promoter in the presence of ORF 50a and C/EBP␣ is due to an increase in the levels of luciferase mRNA, RT-PCR analysis was performed. Total RNA was isolated from 293T cells transfected with either 1 g of pEGFP, p50GFP, or pC/EBP␣ in the presence of 1 g of pORF9-Luc, harvested 24 h posttransfection, and used in RT-PCR analysis to determine the quantities of luciferase mRNA (Fig. 5d) . Results show that in the presence of ORF 50a, luciferase mRNA levels are increased; this is further enhanced upon expression of ORF50a and C/EBP␣. This demonstrates that the transactivation of luciferase re- FIG. 6 . C/EBP␣ binds upstream of the ORF 50 RE within the ORF 9 promoter. (a) Schematic representation of the oligonucleotide primers spanning the potential C/EBP␣ binding site adjacent to the ORF 50 RE within the ORF 9 promoter. The potential C/EBP␣ binding site is boxed. (b) (i) EMSAs were performed using fluorescein-labeled set I and II oligonucleotides spanning the potential C/EBP␣ binding site. Each labeled set of oligonucleotides was incubated with control reticulocyte lysate or in vitro-translated C/EBP␣ or C/EBP␤ and separated on a polyacrylamide gel.
(ii) To demonstrate the specificity of the C/EBP␣ interaction, increased quantities of unlabeled oligonucleotides specific for the C/EBP␣ binding recognition sequence were used to compete out the binding reaction. EMSAs were repeated with a random oligonucleotide.
porter gene from the ORF 9 promoter is due to an increase in mRNA levels.
In vitro-translated C/EBP␣ protein binds directly to the ORF 9 promoter, and binding is required for its transactivation. To determine whether C/EBP␣ binds directly to the ORF 9 promoter, gel retardation experiments were performed using the two sets of oligonucleotides spanning the region between ⌬3 and ⌬3.5, namely, set I-II; set I contains a putative C/EBP␣ binding site identified by Matinspector (Fig. 6a) . The fluorescein-labeled oligonucleotides were incubated with 2.5 l of control reticulocyte lysate or in vitro-translated C/EBP␣ or C/EBP␤. The protein-nucleic acid complexes were then separated and detected by using a variable-mode imager. Results showed the formation of a retarded complex with in vitrotranslated C/EBP␣ when incubated with oligonucleotide set I (Fig. 6bi) . No other complexes were identified, suggesting that C/EBP␣ directly binds the ORF 9 promoter between 20286 and 20314 bp of the published sequence (1). To confirm that the retarded complex detected is specific for C/EBP␣, a competition assay was performed using increasing quantities of unlabeled oligonucleotides spanning a known C/EBP␣ binding previously identified in the KSHV Rta promoter site or a randomized oligonucleotide (39) . The C/EBP␣ oligonucleotides competed out the binding reaction with labeled set I oligonucleotides (Fig. 6bii) , in contrast to the random oligonucleotide, demonstrating that this retarded complex is specific for the C/EBP␣ protein.
To further assess the role of C/EBP␣ on the activation of the ORF 9 promoter, a mutant promoter was generated that contained a deletion within the putative C/EBP␣ recognition sequence, termed pORF9⌬C/EBP␣-Luc. 293T cells were then transfected with 1 g of either pORF9-Luc or pORF9⌬C/ EBP␣-Luc in the presence of 1 g of pEGFP, p50GFP, or pC/EBP␣ and assayed for luciferase activity as described previously (Fig. 7) . The results demonstrated that p50GFP was capable of stimulating both pORF9-Luc or pORF9⌬C/EBP␣-Luc to levels similar to those previously described. However, deletion of the putative C/EBP␣ region resulted in no enhancement of ORF 9 promoter activity in the presence of C/EBP␣, in contrast to the wild-type ORF 9 promoter. This, therefore, suggests that the element responsible for the synergistic response of the ORF 9 promoter in the presence of C/EBP␣ comprises 20286 to 20314 bp of the published sequence within the ORF 9 promoter.
ORF 50a and C/EBP␣ interact with the ORF 9 promoter in vivo. To elucidate whether ORF 50a and C/EBP␣ interact with the ORF 9 promoter in vivo, ChIP assays were performed. Initially, HVS-infected OMK cells were harvested 24 h postinfection. Then ORF 50 and C/EBP␣ were immunoprecipitated using an anti-ORF 50 and anti-C/EBP␣ monoclonal sera, respectively, from the cross-linked protein-DNA complexes. After the removal of the proteins, the recovered DNA was used as a template for the specific amplification of the ORF 9 promoter and a HVS genomic control. Results demonstrate both ORF 50 and C/EBP␣ proteins were found to be specifically associated with the ORF 9 promoter (Fig. 8) . In contrast, the negative controls with anti-ORF 57 antiserum failed to precipitate any ORF 9 promoter. This demonstrates that the ORF 50 and C/EBP␣ interact with the ORF 9 promoter in vivo.
ORF 50a interacts with C/EBP␣. Gel retardation analysis has demonstrated that both ORF 50a and C/EBP␣ bind the ORF 9 promoter in close proximity. Therefore, to investigate whether ORF 50a and C/EBP␣ interact directly with each other, coimmunoprecipitation studies were performed. Control untransfected 293T cells were compared with cells transfected with pEGFP, p50GFP, and a myc-tagged expression construct for C/EBP␣. After 24 h, the cells were harvested, and cell lysates were utilized in coimmunoprecipitation analysis using an anti-ORF 50 antiserum (17) . Polypeptides precipitated from cellular extracts were then analyzed by Western blotting with anti-myc-specific antiserum (Fig. 9 ). The results demonstrate that C/EBP␣ coimmunoprecipitates in the presence of both ORF 50a and the mutant ORF 50a construct lacking its DNA binding domain. This result suggests that the HVS ORF 50a can specifically interact with C/EBP␣ and that the AT-hook DNA binding domain is not required for this interaction.
DISCUSSION
HVS ORF 50a encodes the major transactivator protein which functions as a molecular switch for the transition from latency to lytic replication by specific transactivation of many downstream HVS promoters (36, 37, 41, 42) . Homologues exist in all gammaherpesviruses, and all are thought to function as sequence-specific transactivators (5) . HVS ORF 50 activates transcription by binding to specific REs within their promoter region. In at least some promoters, namely, ORF 6 and ORF 57, a consensus RE which shares homology with the EBV Rta RE element, GNCCN 9 GGNG, has been identified (41, 42) . Guanine methylation studies have demonstrated that the CCN 9 GG motif is essential for EBV Rta binding, suggesting that Rta binds to adjacent major grooves of the DNA (15) . A similar mechanism may function for HVS ORF 50a; however, the flanking sequences are significantly different from those of the EBV Rta REs, suggesting that gammaherpesvirus ORF 50 gene products have different sequences required for recognition and fixation of the proteins to their target. Recent analysis has also suggested that the HVS ORF 50a protein can activate HVS promoters with alternative REs, present within the ORF 50 (37) and now the ORF 9 gene promoters. At present, there is limited homology between these alternative REs; however, they are both AT-rich in sequence. We have recently demonstrated that direct binding to either type of ORF 50 RE requires the ORF 50 DNA binding domain which has a high degree of homology to the DNA binding domain encoded by mammalian HMGA chromosomal proteins termed AT-hook proteins (36) . Previous studies have shown that mammalian AT-hook DNA binding domains have a dynamic confirmation, which allows them to produce optimal contact with the narrow minor groove regions of AT-rich DNA (18, 25, 26) . Therefore, we suggest that due to the absence of direct homology between the two alternative types of REs, the AT-rich DNA sequences are probably being recognized by the ORF 50a AT-hook DNA binding domain.
Interestingly, although all these alternative REs confer ORF 50 responsiveness to a minimal heterologous promoter, the AT-rich RE contained in the ORF 50 and ORF 9 promoters may be less effective than the canonical ORF 6 promoter RE. Perhaps the alternative AT-rich RE found in the ORF 50 and ORF 9 promoters requires additional transcription factor binding sites to be adjacent to the ORF 50 RE for activity to occur, as in the case for the ORF 9 promoter. Although preliminary analysis of the ORF 50 promoter has not identified a similar synergistic response with C/EBP␣ (unpublished observations), this does not rule out the possibility that other cellular transcription factors enhance ORF 50 promoter activity. At present, it is unknown whether this is due to the direct binding FIG. 9 . ORF 50 and C/EBP␣ physically interact. 293T cells were cotransfected with pC/EBP␣-myc in the presence of pEGFP, p50GFP, or p50GFP⌬AT-hook. (a) Cell lysates were immunoprecipitated using anti-ORF 50 antiserum. Bound proteins were resolved by SDS-polyacrylamide gel electrophoresis, and the presence of C/EBP␣-myc was detected using anti-myc antiserum (b). As a control, Western blot analysis was carried out on the supernatants before immunoprecipitation using a anti-GFP antibody to confirm that GFP, 50GFP, and 50GFP⌬AT-hook were expressed in all samples. Untrans, untranslated. affinity of ORF 50a to these different REs. A comparative study of KSHV ORF 50 binding to four target gene promoters demonstrated that KSHV Rta binds to their alternative REs with various affinities (31) . This may result in and partially account for differences in the expression of these Rta target genes. This has led to the hypothesis that these variations in binding affinity could account for multiple genes being expressed at different levels during the lytic replication cycle. Interestingly, the cellular nonhistone DNA architectural protein, HMG-1 may enhance KSHV Rta binding to the REs, particularly the association with the lower affinity REs (32) .
Although the ORF 50 binding affinity may have a role in the level of gene expression, indirect mechanisms are also implicated in gammaherpesvirus ORF 50-mediated transactivation. For example, KSHV Rta can be directed to target promoters through interaction with a cellular transcription factor, RBP-J, the primary target of the Notch signaling pathway (19) . This interaction targets Rta to the RBP-J recognition sequence, resulting in the replacement of RBP-J's repressive action with KSHV Rta-mediated activation. KSHV Rta has also been shown to interact with the cellular DNA binding protein CCAAT/enhancer binding protein alpha (38, 39) . C/EBP␣ is a member of the leucine zipper family of transcription factors which include c-JUN, c-FOS, ATF, and CREB (24) . They have a conserved bZIP domain at the carboxy terminus which can bind to specific DNA binding elements, thereby modulating gene expression (21, 24) . C/EBP␣ promotes differentiation and inhibits cell proliferation, leading to G 1 cell cycle arrest by various mechanisms (21, 24) . As gammaherpesviruses induce G 1 cell cycle arrest during the lytic cycle and C/EBP␣ is known to inhibit cell proliferation, it is an ideal candidate for recruitment by the herpesviruses during the transition into lytic replication. To support this hypothesis, recent analysis has identified an interaction between C/EBP␣ and the KSHV Rta and RAP proteins (38, 39) . These interactions lead to the activation of both viral and cellular protein during the lytic replication cycle via a presumed indirect "piggyback" targeting mechanism to C/EBP␣ binding sites on the gene promoters and also the stabilization of the C/EBP␣ protein. In addition, a direct mechanism may also activate DE KSHV promoters, such as the PAN promoter, whereby ORF 50 and C/EBP␣ both interact directly with the promoter and the ORF50-C/EBP␣ protein complex cooperatively transactivates the promoter (39) .
Herein, we have also demonstrated a direct interaction between HVS ORF 50a and C/EBP␣ and shown they act synergistically to activate the ORF 9 promoter. This demonstrates that C/EBP␣ may well be involved in ORF 50-mediated transactivation of HVS lytic replication. However, the data may not suggest a piggyback mechanism at work. This is supported by a number of points; ORF 50a protein can interact directly with the promoter using gel retardation analysis, but more convincing, the mutant ORF 50a protein 50GFP⌬AT-hook (which contains a deletion of the ORF50 DNA binding domain) fails to transactivate the ORF 9 promoter and C/EBP␣ alone was unable to transactivate the ORF 9 promoter. These results suggest that ORF 50a binding is essential for ORF 9 promoter transactivation. Therefore, it is likely that ORF 50a alone is sufficient to activate the ORF 9 promoter by binding to the AT-rich RE. However, an additional cooperative transactivation mechanism exists; this mechanism is mediated by the ORF50-C/EBP␣ protein complex binding directly to their adjacent binding sites.
In summary, this investigation has described a likely mechanism for the ORF 50-mediated transactivation of the ORF 9 HVS DNA polymerase in the early stages of the lytic replication cycle. This involves the direct binding of both ORF 50a and C/EBP␣ to adjacent binding sites within the ORF 9 promoter.
